Sunflower Pharmaceuticals Group Co Ltd Cash Flow Conversion Efficiency
Sunflower Pharmaceuticals Group Co Ltd cash flow conversion efficiency. Based on the latest financial reports, Sunflower Pharmaceuticals Group Co Ltd (002737) has a cash flow conversion efficiency ratio of -0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-117.97 Million ≈ $-17.26 Million USD) by net assets (CN¥4.23 Billion ≈ $619.26 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sunflower Pharmaceuticals Group Co Ltd (2011–2025)
Cash flow conversion efficiency of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2025. This chart illustrates how Sunflower Pharmaceuticals Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Sunflower Pharmaceuticals Group Co Ltd stock price for real-time trading data and today's change.
Sunflower Pharmaceuticals Group Co Ltd Cash Flow Conversion Ratio Explained
Sunflower Pharmaceuticals Group Co Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sunflower Pharmaceuticals Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sunflower Pharmaceuticals Group Co Ltd ranked by their cash flow conversion efficiency. Also see market value of Sunflower Pharmaceuticals Group Co Ltd for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
C*Core Technology Co Ltd
SHG:688262
|
0.051x |
|
Elecon Engineering Company Limited
NSE:ELECON
|
0.072x |
|
Guangxi Liuzhou Pharm Co Ltd
SHG:603368
|
0.006x |
|
Chengdu CORPRO Technology Co Ltd
SHE:300101
|
0.008x |
|
Wah Lee Industrial Corp
TW:3010
|
0.015x |
|
Medartis Holding AG
SW:MED
|
0.019x |
|
MYT Netherlands Parent BV
NYSE:MYTE
|
0.045x |
|
Drägerwerk AG & Co. KGaA (pref)
F:DRW3
|
0.037x |
Annual Cash Flow Conversion Efficiency for Sunflower Pharmaceuticals Group Co Ltd (2011–2025)
The table below shows the annual cash flow conversion efficiency of Sunflower Pharmaceuticals Group Co Ltd from 2011 to 2025. Review Sunflower Pharmaceuticals Group Co Ltd (002737) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.99 Billion ≈ $583.96 Million |
CN¥574.97 Million ≈ $84.14 Million |
0.144x | +315.08% |
| 2024-12-31 | CN¥4.59 Billion ≈ $671.66 Million |
CN¥-307.48 Million ≈ $-44.99 Million |
-0.067x | -136.31% |
| 2023-12-31 | CN¥5.00 Billion ≈ $732.34 Million |
CN¥923.30 Million ≈ $135.11 Million |
0.184x | -58.45% |
| 2022-12-31 | CN¥4.44 Billion ≈ $649.53 Million |
CN¥1.97 Billion ≈ $288.39 Million |
0.444x | +101.93% |
| 2021-12-31 | CN¥3.94 Billion ≈ $575.83 Million |
CN¥865.23 Million ≈ $126.61 Million |
0.220x | -36.27% |
| 2020-12-31 | CN¥3.39 Billion ≈ $496.17 Million |
CN¥1.17 Billion ≈ $171.19 Million |
0.345x | +20.58% |
| 2019-12-31 | CN¥3.43 Billion ≈ $501.87 Million |
CN¥981.33 Million ≈ $143.60 Million |
0.286x | +13.53% |
| 2018-12-31 | CN¥3.44 Billion ≈ $502.93 Million |
CN¥866.21 Million ≈ $126.75 Million |
0.252x | +42.60% |
| 2017-12-31 | CN¥3.16 Billion ≈ $462.64 Million |
CN¥558.77 Million ≈ $81.77 Million |
0.177x | +45.25% |
| 2016-12-31 | CN¥2.80 Billion ≈ $410.38 Million |
CN¥341.23 Million ≈ $49.93 Million |
0.122x | +152.41% |
| 2015-12-31 | CN¥2.61 Billion ≈ $381.99 Million |
CN¥125.84 Million ≈ $18.41 Million |
0.048x | -72.75% |
| 2014-12-31 | CN¥2.28 Billion ≈ $333.59 Million |
CN¥403.23 Million ≈ $59.00 Million |
0.177x | -47.60% |
| 2013-12-31 | CN¥869.02 Million ≈ $127.17 Million |
CN¥293.34 Million ≈ $42.93 Million |
0.338x | -21.79% |
| 2012-12-31 | CN¥758.39 Million ≈ $110.98 Million |
CN¥327.31 Million ≈ $47.90 Million |
0.432x | -8.95% |
| 2011-12-31 | CN¥543.47 Million ≈ $79.53 Million |
CN¥257.60 Million ≈ $37.70 Million |
0.474x | -- |
About Sunflower Pharmaceuticals Group Co Ltd
Sunflower Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of Chinese medicines in China and internationally. It offers traditional Chinese medicines, chemical drugs, biological drugs, and health and wellness products, as well as adult and children's medicines for various therapeutic areas, including pediatrics, gynecology,… Read more